Products and
Pipeline

Overview¹

TAK-676 is a selective agonist of STimulator of INterferon Genes (STING), a critical molecule for initiating both innate and adaptive immunity via induction of type I interferon response

MOA²

STING signaling activated inflammation

Stimulator of INterferon Genes mediated Type I IFN response plays a core role in:

- Viral clearance

- Bacterial response

- Apoptosis of dying cells

STING signaling in cancer leads to two primary anti-tumors effects

- Activation of innate cells (macrophages, DCs) to produce IFN and “cross-primte” CD8 T cells and also activate NK cells that traffic to tumor

- Induction of tumor cell apoptosis (minor - in tumors with high STING)

Clinical Trials

Study Name

An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

References

1. Takeda, Data on file.

2. O'Neill. Science. 2013.